Wilson Robert J, Freeman Thomas H, Halpern Jennifer L, Schwartz Herbert S, Holt Ginger E
Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Orthopaedic Surgery and Rehabilitation, Vanderbilt University Medical Center, Nashville, Tennessee.
JBJS Rev. 2018 Apr;6(4):e10. doi: 10.2106/JBJS.RVW.17.00072.
Limb-sparing resection and reconstruction for pelvic sarcomas in multiple small studies have been fraught with complications, reoperations, and impaired patient function. However, the non-oncologic complication and reoperation rates and functional outcomes for patients have never been rigorously compiled, to our knowledge. A systematic review was undertaken to more accurately determine the non-oncologic complication and reoperation rates and functional outcomes for patients after pelvic sarcoma resection and reconstruction.
The review was performed in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. PubMed and Cochrane database searches of English-only studies using the terms "pelvis AND sarcoma" and "pelvis AND sarcoma AND surgery" were performed. Study inclusion criteria were ≥10 patients enrolled, at least 12 months of follow-up, utilization of comparable functional outcome measure(s), and the majority of the resections treating primary bone sarcoma.
In this study, 2,350 studies were reviewed, of which 22 Level-IV studies with a total of 801 patients met inclusion criteria. Reconstructive techniques varied widely and included allografts, allograft-prosthesis composites, saddle prostheses, custom endoprostheses, and irradiated autografts. Pooled means showed a mean 5-year patient survival of 55%. The mean non-oncologic complication rate was 49%. The mean non-oncologic reoperation rate was 37%. The mean Musculoskeletal Tumor Society score was 65%.
The non-oncologic complication and reoperation rates for pelvic reconstructions are remarkably high and 5-year survival is poor. Functional outcomes are acceptable but may not be better than a resection of the same Enneking and Dunham type without reconstruction. Consideration should be given to forgoing pelvic reconstruction, especially in patients with poor overall prognosis. Further studies comparing non-oncologic complication rates, reoperation rates, and functional outcomes in patients with equivalent resections treated with or without reconstruction are needed to further elucidate the utility of pelvic reconstruction.
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
多项小型研究表明,骨盆肉瘤的保肢切除与重建手术充满并发症、再次手术以及患者功能受损等问题。然而,据我们所知,患者的非肿瘤性并发症、再次手术率以及功能结局从未得到过严谨的汇总。本研究进行了一项系统评价,以更准确地确定骨盆肉瘤切除与重建术后患者的非肿瘤性并发症、再次手术率以及功能结局。
本评价按照PRISMA(系统评价和Meta分析的首选报告项目)指南进行。在PubMed和Cochrane数据库中检索仅使用英文撰写的研究,检索词为“骨盆 与 肉瘤”以及“骨盆 与 肉瘤 与 手术”。研究纳入标准为纳入患者≥10例、至少随访12个月、使用可比的功能结局测量指标,且大部分切除术用于治疗原发性骨肉瘤。
本研究共检索了2350项研究,其中22项IV级研究共801例患者符合纳入标准。重建技术差异很大,包括同种异体骨移植、同种异体骨-假体复合物、鞍形假体、定制假体以及辐照自体骨移植。汇总均值显示患者5年生存率平均为55%。非肿瘤性并发症平均发生率为49%。非肿瘤性再次手术率平均为37%。肌肉骨骼肿瘤学会平均评分为65分。
骨盆重建的非肿瘤性并发症和再次手术率非常高,5年生存率较差。功能结局尚可,但可能并不优于相同Enneking和Dunham类型的未行重建的切除术。应考虑放弃骨盆重建,尤其是总体预后较差的患者。需要进一步开展研究,比较接受或未接受重建治疗的同等切除术患者的非肿瘤性并发症发生率、再次手术率以及功能结局,以进一步阐明骨盆重建的效用。
治疗性IV级。有关证据级别的完整描述,请参阅作者须知。